Sinovac Biotech Co., Ltd: Influenza, Human trials

The registry lists 25 Influenza, Human studies with Sinovac Biotech Co., Ltd as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 3Phase 3 5Phase 4 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)Not yet recruitingNCT07832201Phase 4
• Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)CompletedNCT07737106Phase 1
• Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenCompletedNCT07211152Phase 3
• Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)CompletedNCT06987942Phase 4
• The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School StudentsActive, not recruitingNCT06208683Phase 4
• Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), InactivatedCompletedNCT05512494Phase 4
• Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05471531Phase 4
• Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, QuadrivalentCompletedNCT05431725Phase 3
• A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 MonthsCompletedNCT05245552Phase 3
• A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years OldCompletedNCT04997239Phase 4
• Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza VaccineCompletedNCT04801888Phase 4
• Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)CompletedNCT03859141Phase 3
• Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)CompletedNCT03853993Phase 3
• The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza VaccineCompletedNCT02269852Phase 4
• The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza VaccineCompletedNCT01736709Phase 4
• Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months InfantsCompletedNCT01047202Phase 4
• Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, AdultsCompletedNCT01008137Phase 4
• A Clinical Trial of Split-virion Influenza A/H1N1 VaccinesCompletedNCT01004653Phase 4
• A Clinical Trial With Influenza A/H1N1 VaccinesCompletedNCT00956111Phase 4
• Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in ChildrenCompletedNCT00900991Phase 2
• Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in AdolescentsCompletedNCT00900588Phase 2
• Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)VaccineCompletedNCT00660257Phase 1
• Phase IV Clinical Trial of an Influenza Split Vaccine AnfluCompletedNCT00556062Phase 4
• Safety and Immunogenicity of an Inactivated Pandemic Influenza VaccineCompletedNCT00535665Phase 2
• Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy SubjectsCompletedNCT00356798Phase 1